BSE · 543616
Trident Lifeline Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹33 Cr with net profit ₹7 Cr — a 20.1% net margin, versus 18.7% the period before.
Shareholding
As of 2026-10-31
- Promoter62.54%
- Public36.1%
- FII1.16%
- DII0.21%
1,054 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.92× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #59 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,51,075 Cr | 36.65 | 5.05 | 13.79% | 17.89% |
| Laurus Labs Limited | ₹1,30,972 Cr | 97.74 | 21.57 | 22.11% | 17.13% |
| Zydus Lifesciences Ltd. | ₹1,18,693 Cr | 26.12 | 4.27 | 15.1% | 14.11% |
| Dr Reddys Laboratories Ltd. | ₹1,15,267 Cr | 41.17 | 2.96 | 7.21% | 8.49% |
| Cipla Ltd. | ₹1,12,442 Cr | 36.21 | 3.18 | 8.18% | 10.39% |
| Mankind Pharma Limited | ₹1,09,044 Cr | 46.73 | 6.23 | 12.76% | 14.58% |
| Aurobindo Pharma Ltd. | ₹1,04,903 Cr | 25.85 | 2.67 | 10.13% | 10.88% |
| Lupin Limited | ₹90,558 Cr | 16.07 | 3.76 | 21.65% | 17.07% |
| Glenmark Pharmaceuticals Ltd. | ₹74,507 Cr | 36.78 | 6.65 | 18.07% | 9.22% |
| Alkem Laboratories Ltd. | ₹61,146 Cr | 28.2 | 4.11 | 13.91% | 13.23% |
| Trident Lifeline Limited(this company) | ₹504 Cr | 22.26 | 4.41 | 19.91% | 14.48% |
AI analysis
AI-generated · google/gemini-2.5-flashTrident Lifeline Limited is listed with a market capitalization of Rs 311 Cr. The company reported a revenue of Rs 95.2 Cr and a profit margin of 14.91%. Its EPS stands at 15.96 and the Price-to-Earnings ratio is 16.35. The stock's 52-week high is Rs 328 and the 52-week low is Rs 229.95.
Positives
- +The Return on Equity (ROE) is 18.97%, indicating efficient use of shareholder funds.
- +The Return on Capital Employed (ROCE) is 18.0518%, reflecting effective utilization of capital.
- +The trailing twelve-month profit margin is 14.91%.
Negatives
- −Promoter holding decreased from 70.0396% on December 31, 2023, to 62.5861% on June 30, 2026.
- −Promoter shares pledged are 6.93% of the total promoter holding as of June 30, 2026.
- −Quarterly net profit decreased from Rs 7.07 Cr in March 2025 to Rs 4.3 Cr in December 2025.
- −No annual EPS data is available for March 2025 or any other annual period beyond the last reported 10.22.
Financial Performance
For the year ending March 2025, Trident Lifeline Limited reported a revenue of Rs 95.1958 Cr and a net profit of Rs 11.7479 Cr. Its annual EPS for the same period was 10.22. In the quarter ending December 2025, the company recorded a revenue of Rs 25.71 Cr and a net profit of Rs 4.3 Cr, with EBITDA at Rs 7.26 Cr. Quarterly revenue for the quarter ending September 2025 was Rs 31.34 Cr with a net profit of Rs 4.95 Cr.
Profitability & Returns
Trident Lifeline Limited achieved a Return on Equity (ROE) of 18.97% and a Return on Capital Employed (ROCE) of 18.0518%. The company's profit margin was 14.91%. The Book Value per share is Rs 84.14.
Balance Sheet
The company maintains a debt-to-equity ratio of 0.62. No dividend yield was reported. The company's market capitalization is Rs 311 Cr, with a Book Value of Rs 84.14.
Ownership & Pledges
As of June 30, 2026, promoter holding in Trident Lifeline Limited stood at 62.5861%. FIIs held 5.2543% and DIIs held 0.2615%. Public shareholding was 31.8981%. A total of 6.93% of promoter shares were pledged as of June 30, 2026, with Desai Hardik Jigishkumar having 517,854 shares pledged, representing 18.78% of his individual holding.
Regulatory & Surveillance
No specific regulatory or surveillance measures have been reported for Trident Lifeline Limited as per the provided data.
Data as of — price: 2026-11-14 · financials: Sep 26 · shareholding: Oct 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.